

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re patent application of:

Confirmation No. 6589

Kimberly A. KELLY et al.

Applic. No.: 10/510,155

Art Unit: 1642

Filed: October 5, 2004

Examiner: Unassigned

For: COLON TUMOR SPECIFIC BINDING PEPTIDES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima* facie prior art reference against the claims of the present application.

RELEVANCE

These documents came to the Applicants' attention during a search of the corresponding international application. A copy of the Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Heller Ehrman LLP

1717 Rhode Island Avenue, NW

Date: October/20 2006

Washington, D.C. 20036

Telephone: (202) 912-2000

Facsimile: (202) 912-2020

Patricia D. Granados

Attorney for Applicant

Reg. No.: 33,683

Customer No. 26633

Substitute for form 1449A/PTO

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/510,166 Application Number October 5, 2004 Filing Date Kimberly A. KELLY et al. First Named Inventor Group Art Unit 1642 **Examiner Name** Unassigned

(use as many sheets as necessary)

38509-0502.US1 of 1 Attorney Docket Number Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A01	CHARLES K. BROWN, MD et al., "A Novel Approach for the Identification of Unique Tumor Vasculature Binding Peptides Using an E. coli Peptide Display Library", Annals of Surgical Oncology, 2000, pp. 743-749, Vol. 7, No. 10	
	A02	JIN GUI et al., "Selection of a Peptide with Affinity for the Tumor-Associated TAG72 Antigen from a Phage-Displayed Library", Biochemical and Biophysical Research Communications, 1996, pp. 414-419, Vol. 218, Article No. 0072	
	A03	KIMBERLY A. KELLY et al., "Isolation of a Colon Tumor Specific Binding Peptide Using Phage Display Selection", Neoplasia, September/October 2003, pp. 437-444, Vol. 5, No. 5	
	A04	FUKUTO MARUTA et al., "Identification of FGF receptor-binding peptides for cancer gene therapy", Cancer Gene Therapy, 2002, pp. 543-552, Vol. 9	
	A05	ULLA B. RASMUSSEN et al., "Tumor cell-targeting by phage-displayed peptides", Cancer Gene Therapy, 2002, pp. 606-612, Vol. 9	
-	A06	ERKKI RUOSLAHTI "Targeting tumor vasculature with homing peptides from phage display", Cancer Biology, 2000, pp. 435-442, Vol. 10	

	· · · · · · · · · · · · · · · · · · ·		T
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.